ATL2: A Potential Drug Target and Biomarker (G64225)

Target Name: ATL2

NCBI ID: G64225

ATL2

ATL2: A Potential Drug Target and Biomarker

ATL2, short for Atypical Twice Layer, is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a member of the tyrosine kinase family and is involved in the regulation of cell growth, differentiation, and survival. ATL2 has also been shown to play a role in the development and progression of various diseases, including cancer. As a result, ATL2 has emerged as a promising drug target and biomarker for a variety of diseases.

The discovery and characterization of ATL2 began in the late 1990s, when researchers identified it as a protein that was expressed in the brain and was involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Subsequent studies revealed that ATL2 was involved in the regulation of several important cellular processes, including cell survival, proliferation, and differentiation.

One of the key functions of ATL2 is its role in the regulation of cell survival.ATL2 has been shown to play a role in the regulation of cell survival by promoting the production of Bcl-2, a protein that can help to protect cells from stress and damage. Bcl-2 has also been shown to promote the growth and survival of cancer cells, making it a potential drug target for cancer.

In addition to its role in cell survival, ATL2 is also involved in the regulation of cell proliferation. Studies have shown that ATL2 is involved in the regulation of cell proliferation by promoting the production of cyclin D1, a protein that can help to control the cycle of cell division. This function of ATL2 has implications for the development of cancer, as cancer cells are able to evade the normal controls on cell proliferation.

Another function of ATL2 is its role in the regulation of cell differentiation.ATL2 has been shown to play a role in the regulation of cell differentiation by promoting the production of transforming growth factor-beta (TGF-beta), a protein that is involved in the regulation of cell growth and differentiation. TGF-beta has been shown to promote the development of cancer, making it a potential drug target for cancer.

In addition to its role in cell survival, proliferation, and differentiation, ATL2 is also involved in the regulation of cell signaling. Studies have shown that ATL2 is involved in the regulation of several signaling pathways, including the TGF-beta signaling pathway. This function of ATL2 has implications for the development of diseases that are caused by disruptions in cell signaling, such as cancer.

The identification of ATL2 as a potential drug target and biomarker has led to a significant amount of research into its functions and the potential mechanisms of its action. As a result of this research, it is clear that ATL2 plays a critical role in the regulation of cellular processes that are important for the development and maintenance of health. The continued characterization of ATL2 and its potential as a drug target and biomarker will be an important area of research in the years to come.

Protein Name: Atlastin GTPase 2

Functions: GTPase tethering membranes through formation of trans-homooligomers and mediating homotypic fusion of endoplasmic reticulum membranes. Functions in endoplasmic reticulum tubular network biogenesis (PubMed:18270207, PubMed:19665976, PubMed:27619977)

The "ATL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets